866914-87-6
Chemical Structure
ARL 17477
- CAS No.: 866914-87-6
- Formula:C20H22Cl3N3S
- Molecular Weight:442.83
IUPAC Name: N-(4-(2-((3-chlorobenzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide dihydrochloride
InChIKey: SOXBYIKSUDXMIE-UHFFFAOYSA-N
SMILES: [H]Cl.[H]Cl.N=C(C1=CC=CS1)NC2=CC=C(CCNCC3=CC(Cl)=CC=C3)C=C2
Biological Activity: ARL 17477 is a blood-brain barrier-penetrant selective neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 1 μM. ARL 17477 reduces nitric oxide production and activates TFEB and lysosomal biogenesis, induces lysosomal membrane permeabilization, but inhibits autophagy-lysosomal function, autophagic flux, protein aggregate clearance, and proliferation. ARL 17477 induces ERK hyperphosphorylation and slight AKT inhibition. ARL 17477 exhibits NOS1 -independent anticancer activity against multiple cancer cells. ARL 17477 inhibits xenograft tumor growth in vivo. ARL 17477 can be used in research on colon cancer, non-small cell lung cancer, osteosarcoma, pancreatic cancer, arterial occlusion, and pain[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ARL 17477 | 98.88% | ARL 17477 is a blood-brain barrier-penetrant selective neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 1 μM. ARL 17477 reduces nitric oxide production and activates TFEB and lysosomal biogenesis, induces lysosomal membrane permeabilization, but inhibits autophagy-lysosomal function, autophagic flux, protein aggregate clearance, and proliferation. ARL 17477 induces ERK hyperphosphorylation and slight AKT inhibition. ARL 17477 exhibits NOS1 -independent anticancer activity against multiple cancer cells. ARL 17477 inhibits xenograft tumor growth in vivo. ARL 17477 can be used in research on colon cancer, non-small cell lung cancer, osteosarcoma, pancreatic cancer, arterial occlusion, and pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ARL 17477 (Standard) | ≥98% | ARL 17477 (Standard) is the analytical standard of ARL 17477 (HY-107720). This product is intended for research and analytical applications. ARL 17477 is a blood-brain barrier-penetrant selective neuronal nitric oxide synthase (nNOS) inhibitor with an IC50 of 1 μM. ARL 17477 reduces nitric oxide production and activates TFEB and lysosomal biogenesis, induces lysosomal membrane permeabilization, but inhibits autophagy-lysosomal function, autophagic flux, protein aggregate clearance, and proliferation. ARL 17477 induces ERK hyperphosphorylation and slight AKT inhibition. ARL 17477 exhibits NOS1 -independent anticancer activity against multiple cancer cells. ARL 17477 inhibits xenograft tumor growth in vivo. ARL 17477 can be used in research on colon cancer, non-small cell lung cancer, osteosarcoma, pancreatic cancer, arterial occlusion, and pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. O'Neill MJ, et al. ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain research. 2000 Jul 21;871(2):234-44.
- [2]. Nomura TK, et al. ARL-17477 is a dual inhibitor of NOS1 and the autophagic-lysosomal system that prevents tumor growth in vitro and in vivo. Scientific reports. 2023 Jul 04;13(1):10757. [Content Brief]
- [3]. Pendharkar AV, et al. Optogenetic Stimulation Reduces Neuronal Nitric Oxide Synthase Expression After Stroke. Translational stroke research. 2021 Apr;12(2):347-356.
- [4]. Oberkrom K, et al. Targeting GPR183 to reduce peripheral sensitization: evidence from rodent and human tissue analyses. bioRxiv. 2026 Jan 16:2026-01. [Content Brief]
